Bibliography
- CUATRECASAS PJ: Drug discovery in jeopardy. Clin. Invest. (2006) 116(11):2837-2842.
- GERLAG DM, HARINGMAN JJ, SMEETS TJ et al.: Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum. (2004) 50(12):3783-3791.
- SUNTHARALINGAM G, PERRY MR, WARD S et al.: Cytokine storm in a Phase I trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. (2006) 355:1-11.
- WEISSLEDER R, MAHMOOD U: Molecular imaging. Radiology (2001) 219(2):316-333.
- BOWSER P, SHYJAN A: Biomarker world congress 2005. Personalized Med. (2005) 2(3):209-212.
- KOLA I, LANDIS J: Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. (2004) 3(8):711-715.
Websites
- http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdfStagnation and innovation: challenge and opportunity on the critical path to new medical products (2004).
- http://www.ich.org/LOB/media/MEDIA506.pdfMaintenance of the ICH guideline on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals. M3(R1).
- http://www.emea.eu.int/pdfs/human/swp/259902en.pdfPosition paper on non-clinical safety studies to support clinical trials with a single microdose.
- http://www.dh.gov.uk/assetRoot/04/14/10/43/04141043.pdfExpert scientific group on Phase one clinical trials. Final report. 30 November 2006.